Steelers Aaron Smith's Son has Leukemia

Smith's son, Elijah, who turned 5 Dec. 6, was diagnosed with Acute Lymphoblastic Leukemia -- a cancer of the white blood cells -- a few days before the Steelers played the New York Giants Oct. 26. The disease has an 80 percent survival rate, the doctors told Smith and his wife, Jaimie. They are encouraged about Elijah because he has responded well to once-a-week chemotherapy treatments and his follow-up blood tests have been good.

You wouldn't know he had leukemia if you talked to him," said Smith. "He's a cheerful, happy boy. If he wasn't bald you probably wouldn't even know he's in chemo."

Elijah had to have blood transfusions four, five, maybe even six times," Smith said. "There's such a shortage of blood. I don't think people understand the difference they can make in people's lives by donating. I didn't understand. But you're talking about saving someone's life."

Smith is asking people to donate blood as well as text LLS and donate $5 to the Leukemia & Lymphoma Society.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap